Krystal Biotech (KRYS) EVP executes 10b5-1 option exercise and 1,000-share sale

Rhea-AI Filing Summary

Krystal Biotech EVP and General Counsel Thomas John Charles reported an exercise-and-sale transaction in company stock. He exercised stock options to acquire 1,000 shares of common stock at $179.25 per share and then sold 1,000 shares in an open-market transaction at $347.27 per share, leaving him with no directly held common shares. Following the derivative transaction, he continued to hold 6,500 stock options expiring on February 27, 2035. According to a footnote, both the acquisition and sale were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 23, 2026, and that plan has now fully completed and terminated.

Insights

Equity compensation analyst

Pre-planned option exercise and full same-day sale; routine liquidity.

The filing shows EVP and General Counsel Thomas John Charles exercising options on 1,000 shares at a strike price of $179.25 and selling all 1,000 shares at $347.27. This is a classic exercise-and-sell pattern converting an equity award into cash.

A key detail is the footnote stating the acquisition and sale occurred under a Rule 10b5-1 trading plan adopted on February 23, 2026, with all plan transactions now completed. Such pre-planned trades are typically scheduled in advance, reducing the informational value of the exact timing.

After these transactions, he holds no common shares directly but retains 6,500 stock options expiring on February 27, 2035. This indicates he still has meaningful exposure tied to the company’s equity through remaining unexercised options even though his directly held shares are currently zero.

Insider Trade Summary 10b5-1

Net Seller: 1,000 shares ($347,270)

Net Sell 3 txns

Insider Thomas John Charles

Role EVP, General Counsel

Sold 1,000 shs ($347K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	1,000	$0.00	--
Exercise	Common Stock	1,000	$179.25	$179K
Sale	Common Stock	1,000	$347.27	$347K

Holdings After Transaction: Stock Option (Right to Buy) — 6,500 shares (Direct, null); Common Stock — 1,000 shares (Direct, null)

Footnotes (1)

1. The acquisition and sale of shares of the Company's common stock reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 23, 2026. All transactions contemplated by the plan have been completed, and the plan has terminated in accordance with its terms. The options vest ratably over a four-year period beginning on February 28, 2026.

Key Figures

Shares sold: 1,000 shares Sale price: $347.27 per share Options exercised: 1,000 shares +3 more

6 metrics

Shares sold 1,000 shares Open-market sale of common stock on June 25, 2026

Sale price $347.27 per share Price for 1,000 common shares sold

Options exercised 1,000 shares Stock option exercise into common stock

Option strike price $179.25 per share Conversion or exercise price of stock options

Remaining options 6,500 options Stock options outstanding after exercise, expiring February 27, 2035

10b5-1 plan adoption date February 23, 2026 Date trading plan governing transactions was adopted

Key Terms

Rule 10b5-1 trading plan, Stock Option (Right to Buy), Exercise or conversion of derivative security, open-market sale

4 terms

Rule 10b5-1 trading plan regulatory

"were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

Exercise or conversion of derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security""

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/26/2026 - 06:46 PM Accepted by SEC EDGAR 06/26/2026 - 06:45 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Thomas John Charles

(Last) (First) (Middle)

C/O KRYSTAL BIOTECH, INC.

2100 WHARTON STREET, SUITE 701

(Street)

PITTSBURGH PENNSYLVANIA 15203

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Krystal Biotech, Inc. [ KRYS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, General Counsel

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/25/2026		M		1,000(1)	A	$179.25	1,000	D
Common Stock	06/25/2026		S		1,000(1)	D	$347.27	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$179.25	06/25/2026		M			1,000	(2)	02/27/2035	Common Stock	1,000	$0	6,500	D

Explanation of Responses:

1. The acquisition and sale of shares of the Company's common stock reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 23, 2026. All transactions contemplated by the plan have been completed, and the plan has terminated in accordance with its terms.

2. The options vest ratably over a four-year period beginning on February 28, 2026.

Remarks:

	/s/ John C. Thomas	06/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Krystal Biotech (KRYS) report for Thomas John Charles?

Krystal Biotech reported that EVP and General Counsel Thomas John Charles exercised options for 1,000 common shares at $179.25 and sold 1,000 shares at $347.27. The exercise-and-sale pattern converted stock option value into cash in a single sequence of transactions.

Was the KRYS insider sale by Thomas John Charles part of a Rule 10b5-1 plan?

Yes. The filing states the acquisition and sale of Krystal Biotech common stock occurred under a Rule 10b5-1 trading plan adopted on February 23, 2026. All transactions under that plan have been completed and the plan has terminated according to its terms.

How many Krystal Biotech shares did the EVP and General Counsel sell and at what price?

He sold 1,000 shares of Krystal Biotech common stock in an open-market transaction at an average price of $347.27 per share. This disposition followed the exercise of stock options covering the same 1,000 underlying shares at a lower strike price.

What stock options does Thomas John Charles still hold in Krystal Biotech after this Form 4?

After exercising 1,000 options, he holds 6,500 stock options with a conversion or exercise price of $179.25 per share, expiring on February 27, 2035. These remaining options continue to link part of his compensation to Krystal Biotech’s future share performance.

Did the Krystal Biotech insider retain any common shares after the reported transactions?

The sale transaction line shows zero common shares directly held following the 1,000-share sale. However, he continues to hold 6,500 stock options, so his exposure is now through derivative equity awards rather than directly owned common stock.